In various cancers, increased levels of IFN-γ signaling, either in tumor tissue or peripheral blood, are associated with enhanced immune activity and are significantly correlated with longer overall survival (OS), progression-free survival (PFS), and improved response rates to immune checkpoint inhibitors (ICBs) (7). Here, IFNG is linked to cancer.